DREAM Study: DNA/RNA-NGS Co-Testing in Driver-Negative, Treatment-Resistant NSCLC

Inclusion Criteria

• •1. Aged 18 and above, male or female
• •2. Pathologically diagnosed with advanced or metastatic inoperable non-small cell lung cancer
• •3. Prior genetic testing \[DNA-NGS\] results show no mutations in EGFR, BRAF, MET, HER2, KRAS, FGFR2/3，no amplifications in MET and HER2 and no fusions in ALK, ROS1, RET, NTRK, NRG1, EGFR, MET, BRAF, FGFR2/3
• •4. Based on negative driver gene results, received first-line non-targeted therapy with rapid progression or intolerance, with a progression-free survival (PFS) of ≤6 months (regardless of drug exposure time, calculated from the first day of medication)
• •5. Have retained tumor tissue samples prior to first-line treatment
• •6. Patients are from medical centers that can ethically affiliate and have accessible clinical follow-up data.
• •2. Presence of other pulmonary diseases that require treatment or are severe, including but not limited to active pulmonary tuberculosis, interstitial lung disease, etc.
• •3. Presence of active infections that require systemic treatment
• •4. History of drug abuse or alcohol abuse, or mental illness, or suspected allergy or intolerance to the study drug or any of its components
• •5. Any other conditions deemed unsuitable for entry into this study by the investigator.